InnoCare Pharma Ltd. A (SHG:688428) — Market Cap & Net Worth
Market Cap & Net Worth: InnoCare Pharma Ltd. A (688428)
InnoCare Pharma Ltd. A (SHG:688428) has a market capitalization of $1.21 Billion (CN¥8.27 Billion) as of April 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #8594 globally and #2074 in its home market, demonstrating a 4.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InnoCare Pharma Ltd. A's stock price CN¥30.80 by its total outstanding shares 268359717 (268.36 Million).
InnoCare Pharma Ltd. A Market Cap History: 2022 to 2026
InnoCare Pharma Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $554.09 Million to $1.21 Billion (39.69% CAGR).
InnoCare Pharma Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InnoCare Pharma Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.48x
InnoCare Pharma Ltd. A's market cap is 0.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $554.09 Million | $625.40 Million | -$886.59 Million | 0.89x | N/A |
| 2023 | $451.60 Million | $738.54 Million | -$631.26 Million | 0.61x | N/A |
| 2024 | $482.23 Million | $1.01 Billion | -$440.63 Million | 0.48x | N/A |
Competitor Companies of 688428 by Market Capitalization
Companies near InnoCare Pharma Ltd. A in the global market cap rankings as of April 21, 2026.
Key companies related to InnoCare Pharma Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #298 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #455 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #456 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #298 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #455 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #456 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
InnoCare Pharma Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, InnoCare Pharma Ltd. A's market cap moved from $554.09 Million to $ 1.21 Billion, with a yearly change of 39.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.21 Billion | +50.10% |
| 2025 | CN¥805.81 Million | +67.10% |
| 2024 | CN¥482.23 Million | +6.78% |
| 2023 | CN¥451.60 Million | -18.50% |
| 2022 | CN¥554.09 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 20th, 2026 the market cap of InnoCare Pharma Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.21 Billion USD |
| MoneyControl | $1.21 Billion USD |
| MarketWatch | $1.21 Billion USD |
| marketcap.company | $1.21 Billion USD |
| Reuters | $1.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About InnoCare Pharma Ltd. A
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone l… Read more